Construction of Escherichia coli strains with chromosomally integrated expression cassettes for the synthesis of 2′-fucosyllactose
© Baumgärtner et al.; licensee BioMed Central Ltd. 2013
Received: 23 January 2013
Accepted: 22 April 2013
Published: 1 May 2013
The trisaccharide 2′-fucosyllactose (2′-FL) is one of the most abundant oligosaccharides found in human milk. Due to its prebiotic and anti-infective properties, 2′-FL is discussed as nutritional additive for infant formula. Besides chemical synthesis and extraction from human milk, 2′-FL can be produced enzymatically in vitro and in vivo. The most promising approach for a large-scale formation of 2′-FL is the whole cell biosynthesis in Escherichia coli by intracellular synthesis of GDP-L-fucose and subsequent fucosylation of lactose with an appropriate α1,2-fucosyltransferase. Even though whole cell approaches have been demonstrated for the synthesis of 2′-FL, further improvements of the engineered E. coli host are required to increase product yields. Furthermore, an antibiotic-free method of whole cell synthesis of 2′-FL is desirable to simplify product purification and to avoid traces of antibiotics in a product with nutritional purpose.
Here we report the construction of the first selection marker-free E. coli strain that produces 2′-FL from lactose and glycerol. To construct this strain, recombinant genes of the de novo synthesis pathway for GDP-L-fucose as well as the gene for the H. pylori fucosyltransferase futC were integrated into the chromosome of E. coli JM109 by using the λ-Red recombineering technique. Strains carrying additional copies of the futC gene and/or the gene fkp (from Bacteroides fragilis) for an additional salvage pathway for GDP-L-fucose production were used and shown to further improve production of 2′-FL in shake flask experiments. An increase of the intracellular GDP-L-fucose concentration by expression of fkp gene as well as an additional copy of the futC gene lead to an enhanced formation of 2′-FL. Using an improved production strain, feasibility of large scale 2′-FL production was demonstrated in an antibiotic-free fed-batch fermentation (13 l) with a final 2′-FL concentration of 20.28 ± 0.83 g l-1 and a space-time-yield of 0.57 g l-1 h-1.
By chromosomal integration of recombinant genes, altering the copy number of these genes and analysis of 2′-FL and intracellular GDP-L-fucose levels, we were able to construct and improve the first selection marker-free E. coli strain which is capable to produce 2′-FL without the use of expression plasmids. Analysis of intracellular GDP-L-fucose levels identified the de novo synthesis pathway of GDP-L-fucose as one bottleneck in 2′-FL production. In antibiotic-free fed-batch fermentation with an improved strain, scale-up of 2′-FL could be demonstrated.
KeywordsGDP-L-fucose 2′-fucosyllactose Chromosomal integration Human milk oligosaccharides
With approximately 5 to 15 g l-1, human milk oligosaccharides (HMOs) are the third most abundant solid component of human milk after lactose and lipids . All HMOs consist of a core structure containing at least lactose at the reducing end and can be extended with N-acetyllactosamine (LacNAc) units (type I or II) in a linear or branched form. The structural diversity of HMOs is further expanded by the extensive addition of L-fucose and/or sialic acid residues to terminal positions resulting in over 200 different compounds identified so far [2, 3]. The concentrations of different HMOs and their total amount in human milk vary within the lactation phase and between individuals, which is believed to be partially based on genetic background [4, 5]. Importantly, however, HMOs are not found in comparable abundances in other natural sources, like cow, sheep, or goat milk . Several beneficial effects of HMOs on infants have been shown or suggested, including selective enhancement of bifidobacterial growth, anti-adhesive effects on pathogens and glycome-altering effects on intestinal epithelial cells [7–10]. Moreover, infants’ nutrition containing 2′-fucosyllactose (2′-FL) is associated with lower rates of diarrhea, making 2′-FL a potential nutritional supplement and therapeutic agent, if it were available in sufficient amounts and at a reasonable price .
Formerly, 2′-FL has been obtained via extraction from human milk or chemical synthesis [12, 13], but the limited availability of human milk or the necessity of side group protection and deprotection in chemical synthesis, respectively, set limits to supply and cost efficiency. Thus, alternative sources of 2′-FL became of interest. With the identification and functional heterologous expression of an α1,2-fucosyltransferase (FutC) from Helicobacter pylori, which can utilize lactose as acceptor substrate , the research for a biotechnological alternative of 2′-FL production was enhanced.
FutC from H. pylori and the recently characterized WbsJ from E. coli O128:B12 are regio- and stereoselective α1,2-fucosyltransferases which connect the fucosyl-group in α-linkage to the 2-position of the galactosyl-residue of saccharides such as N-acetyllactosamine or lactose [15, 16].
An enzymatic in vitro fucosylation of lactose to 2′-FL was accomplished by the use of recombinant α1,2-fucosyltransferase (FutC) from H. pylori and enzymatically prepared GDP-L-fucose . But in particular the efforts and expenses for the preparation of GDP-L-fucose make this approach inapplicable for a large-scale production of 2′-FL. A large-scale biotransformation system for fucosylated sugars depending on a mixture of permeabilized Corynebacterium ammoniagenes and different E. coli cells was demonstrated by Koizumi et al.. In this system, C. ammoniagenes was utilized for GTP regeneration, whereas different E. coli strains, expressing genes for GDP-L-fucose biosynthesis and fucosyltransferase, were used for the production of GDP-L-fucose and fucosylated oligosaccharides.
Whole cell biosynthesis of 2′-FL was carried out employing E. coli strains that provide endogenous GDP-L-fucose and overexpress α1,2-fucosyltransferase. To obtain sufficient amounts of GDP-L-fucose for cytoplasmic fucosylation reactions, different strategies were followed. It has been shown that GDP-L-fucose formation can be achieved by overexpression of plasmid-borne genes (manB, manC, gmd, wcaG) of the GDP-L-fucose de novo pathway [24, 25]. In another approach, Dumon et al. used plasmids to overexpress the gene for the positive regulator protein of the colanic acid biosynthesis, RcsA in an E. coli strain with inactivated wcaJ gene encoding the UDP-glucose lipid carrier transferase. This resulted in synthesis of GDP-L-fucose but avoided the formation of colanic acid.
So far, all approaches for the whole-cell synthesis of fucosylated oligosaccharides relied on the expression of plasmid-borne genes to obtain the necessary proteins. Expression plasmids are expedient for cloning and short-term expression of recombinant genes, in particular for the maximum overproduction of a given protein. For the in vivo synthesis of a natural product in a bacterial host, where multiple genes have to be expressed, the use of expression plasmids has several disadvantages. Plasmids tend to structural and segregational instability, that can lead to the loss or inactivation of the genes to be expressed . To maintain expression plasmids in the cell, selection markers, like antibiotic resistance genes or plasmid addiction systems, are required. Such selection systems lead to the loss of viability of plasmid-free cells, but cannot avoid segregational instability. Moreover the metabolic burden of plasmid replication and the strong overexpression of certain genes can lead to reduced growth rates and increased demand of energy and metabolites for the additional pathway . Most importantly, in processes aimed for human nutrition, the use of antibiotics is either legally forbidden or undesired for cost reasons. In addition, removal of antibiotics in downstream processing is elaborate and expensive.
To avoid these disadvantages, stable insertion of recombinant genes into the chromosome of the bacterial host may be desired. The chromosomal integration allows the maintenance of recombinant genes without the use of selection marker. For Escherichia coli, several methods have been developed for the insertion of expression cassettes into chromosome and its use for the synthesis of value products [29–33].
In the present study, we have constructed an E. coli strain carrying individual expression cassettes of genes on the chromosome to allow synthesis of GDP-L-fucose or 2′FL. Using this strain as platform, experiments were carried out to identify possible bottlenecks in GDP-L-fucose supply and fucosylation activity. After chromosomal integration of an additional copy of the fucosyltransferase gene, fed-batch fermentation was conducted to obtain higher yields of 2′-FL on a 13 liter scale in an antibiotic-free process.
Construction of 2′-FL producing Escherichia coli strains
Bacterial strains and plasmids used in this study
Relevant genotype or sequences
Source or reference
E. coli DH5α
F-, ϕ80d, lacZ ΔM15, endA 1, recA 1, hsdR 17(rK-mK-), supE 44, thi-1, gyrA 96, relA 1, Δ(lacZYA-argF)U169
E. coli JM109
F′ traD36 proA + B + lacI q Δ (lacZ)M15/ Δ (lac-proAB) glnV44 e14 - gyrA96 recA1 relA1 endA1 thi hsdR17
E. coli JM109 gwBC
E. coli JM109, rbsDK::manC, melAB::manB, xylAB::gmdwcaG
E. coli JM109 gwBC-F1
E. coli JM109, rbsDK::manC, melAB::manB, xylAB::gmdwcaG, malEG::futC
E. coli JM109 gwBC-F1-fkp
E. coli JM109, rbsDK::manC, melAB::manB, xylAB::gmdwcaG, malEG::futC, fucIK ::fkp
E. coli JM109 gwBC-F2
E. coli JM109, rbsDK::manC, melAB::manB, xylAB::gmdwcaG, malEG::futC, fucIK ::futC
E. coli JM109 gwBC-F2-fkp
E. coli JM109, rbsDK::manC, melAB::manB, xylAB::gmdwcaG, malEG::futC, fucIK::futC, araBAD::fkp
ParaB γ β exo (red recombinase), AmpR
FLP+, λ cI857+, λ pR Repts, AmpR, CmR
pET16b, B. fragilis fkp gene, AmpR
pET11a, S. enterica manB gene, AmpR
Albermann & Piepersberg (unpublished)
pET11a, S. enterica manC gene, AmpR
Albermann & Piepersberg (unpublished)
pJOE2775, H. pylori futC gene, AmpR
pJF119ΔN, P. ananatis crtE gene, FRT-sites, AmpR, CmR
pJF119ΔN, P. ananatis crtY gene, FRT-sites, AmpR, KanR
pQE31, FRT-sites, AmpR, CmR
cloning vector, RBS, Ptac, AmpR
pJF119ΔN, S. enterica manB gene, AmpR
pJF119ΔN, S. enterica manC gene, AmpR
pJF119ΔN, E. coli gmd, wcaG gene, AmpR
pJF119ΔN, H. pylori futC gene, AmpR
pJF119ΔN, B. fragilis fkp gene, AmpR
pJF119ΔN, S. enterica manB gene, FRT-sites, AmpR, CmR
pJF119ΔN, S. enterica manC gene, FRT-sites, AmpR, KanR
pJF119ΔN, E. coli gmd, wcaG gene, FRT-sites, AmpR, CmR
pJF119ΔN, H. pylori futC gene, FRT-sites, AmpR, CmR
pJF119ΔN, B. fragilis fkp gene, FRT-sites, AmpR, CmR
Determination of intracellular GDP-L-fucose levels and 2′-fucosyllactose formation
Genetic stability of the E. coli strain JM109 gwBC-F2 was analyzed under the assumption, that loss or mutation of the chromosomally integrated cassettes would result in shifts of the 2′-FL production rates or in the complete abolition of 2′-FL formation. For this, the strain JM109 gwBC-F2 was cultivated in minimal medium for several days with transfer to shake flask with new medium each 24 hours until it reached over 100 generations. When comparing 2′-FL yields in minimal medium with 0.2% lactose 24 hours after induction, cultures that had been cultivated for more than 100 generations still showed 95.01 ± 1.88% of the 2′-FL yield, observed in reference cultivations.
Production of 2′-FL by fed-batch cultivation
Oligosaccharides found in human milk have been shown to be beneficial for the infants’ health. HMOs have been reported to serve as selective growth factor for specific bacteria such as Lactobacilli or Bifidobacteria  and they function as anti-adhesive antimicrobials that inhibit the adhesion of pathogenic viruses or bacteria to epithelial cells . Furthermore, small quantities of HMOs may also be absorbed into the gastrointestinal tract where they modulate epithelial and immune cell response .
It was shown by in vitro and in vivo studies that 2′-FL has an anti-adhesive effect against Campylobacter jejuni and thereby lowers the risk of bacterial diarrhea caused by this organism [11, 42]. In addition, 2′-FL selectively promotes the growth of bifidobacteria . Due to these important biological activities of HMOs, efficient ways for HMO synthesis are needed. Currently, both chemical and enzymatic approaches are used for the formation of 2′-FL [13, 14, 25, 44, 45]. Especially the enzymatic formation of 2′-FL using a recombinant in vivo biosynthesis approach is to the best advantage, because co-factors like NADPH and GTP, needed for the enzymatic synthesis of GDP-L-fucose, can be regenerated in situ by the metabolism of the cell. For the in vivo production of 2′-FL by E. coli the expression of a GDP-L-fucose biosynthesis pathway and of a α1,2-fucosyltransferase are prerequisites. In previous studies, the intracellular formation of GDP-L-fucose in E. coli was achieved by the expression of the de novo biosynthesis genes manB, manC, gmd, and wcaG or by the RcsA-mediated activation of the native de novo pathway [24, 26, 46]. The α1,2-transfer of the L-fucosyl group from GDP-L-fucose to lactose can be achieved by the heterologous expression of the promiscuous α1,2-fucosyltransferase FutC from H. pylori[14, 45, 47].
So far, plasmids have been used for the expression of a heterologous 2′-FL biosynthesis pathway in E. coli strains, but the use of expression plasmids, in particular for large scale bioreactor cultivation, has several disadvantages. Plasmids tend to structural and segregational instability and therefore require a selection marker, like an antibiotic resistance gene, to maintain propagation of the plasmid in the cell . For applications in food industry, especially the addition of antibiotics is undesirable. Furthermore the imbalanced expression of a few biosynthesis genes, either by high copy plasmids and/or strong promoters, can cause a metabolic burden effect and, thus, may lower product and/or biomass yield [28, 48]. In the present study, to avoid the negative effects caused by plasmid-based expression, the required biosynthesis genes were integrated into the chromosome of E. coli as previously described . Thus, up to six individual expression cassettes were established in the chromosome by replacing dispensable sugar degradation genes. Concerning the stability of the inserted biosynthesis genes we want to point out that chromosomal DNA is subject to evolutionary modifications by recombination or point mutation, but so far we have no evidence that the integrated expression cassettes tend to higher structural instability.
In contrast to previous works that used E. coli JM109 (DE3) as host for 2′-FL production [25, 45], E. coli JM109, which has no detectable β-galactosidase activity, was employed to ensure the complete conversion of the lactose, assimilated via LacY, to 2′-FL (Figure 1). With the construction of the strain JM109 gwBC-F1, and the subsequent shake flask cultivations, we created an expression plasmid-free E. coli strain producing 206.16 mg gCDW-1 2′-FL from lactose in minimal medium shake flask cultivation with glycerol as carbon source (Figure 5A). To improve 2′-FL productivity, strain development was used to identify possible bottlenecks in the in vivo fucosylation pathway. For the enzymatic formation of GDP-L-fucose the de novo synthetic and the salvage synthetic pathways have been described [17, 19, 20]. Here, in addition to the recombinant GDP-L-fucose de novo pathway, the salvage pathway was established in E. coli in order to modulate the intracellular GDP-L-fucose concentration. The salvage pathway requires the supply of L-fucose to the medium, from where the uptake is mediated by FucP. The intracellular degradation of L-fucose was prevented by the knock-out of fucI and fucK via the insertion of an expression cassette into fucIK (Figure 2). The additional GDP-L-fucose salvage pathway in a strain expressing the de novo pathway yielded an about 10 times higher intracellular concentration of the activated 6-deoxyhexose up to 5.1 mg gCDW-1. In a strain using only the de novo pathway, the lower GDP-L-fucose content maybe contributed to the feed-back inhibition of GDP-mannose-4,6-dehydratase by GDP-L-fucose [20, 49, 50]. Studies by Lee et al.[46, 51] showed that the GDP-L-fucose content in the cell can be increased by the high expression of manB, manC, gmd, and wcaG as well as by the higher availability of NADPH in the cell with concentrations up to 2.8 mg gCDW-1.
Comparison of E. coli JM109 gwBC-F1 with E. coli JM109 gwBC-fkp-F1 showed an increase in 2′-FL productivity of over 80% with the salvage pathway of GDP-L-fucose synthesis indicating a bottleneck in the GDP-L-fucose supply for the fucosylation reaction in JM109 gwBC-F1 (Figure 5A). It should also be noted that the biomass yield of strains using the salvage pathway is significantly increased, reflecting a probable metabolite saving as the fucose-residue of 2′-FL mainly does not need to be withdrawn from anabolism, but is added with the fed fucose.
An increase in productivity of about 25% was observed with E. coli JM109 gwBC-F2 carrying an additional futC expression cassette on the chromosome compared to E. coli JM109 gwBC-F1. However, only a marginal increase in 2′-FL yield was seen by cultivations of E. coli JM109 gwBC-fkp-F2 compared to E. coli JM109 gwBC-fkp-F1. Thereby it can be concluded that, for the here reported basic 2′-FL producing strain E. coli JM109 gwBC-F1, both the expression of the fucosyltransferase as well as the supply of GDP-L-fucose represent rate limiting factors towards the in vivo synthesis of 2′-FL. Whereas the supply of GDP-L-fucose, that could be increased by the use of the salvage pathway, had the strongest effect on the in vivo 2′-FL formation.
In order to demonstrate an upscale of the 2′-FL synthesis using an expression plasmid-free production strain, a fed-batch cultivation of E. coli JM109 gwBC-F2 with glycerol as C- and energy source and lactose as substrate was conducted. Focusing on the production of high concentrations of 2′-FL combined with small amounts of remaining lactose to simplify the product purification process, a final product concentration of 20.28 ± 0.83 g l-1 could be achieved in a total process time of about 35.5 hours. With a final culture volume of 13.5 liters, a total amount of 273 g 2′-fucosyllactose and a space time yield of about 0.57 g l-1 h-1 were reached.
Compared to a fed-batch cultivation using E. coli with two expression plasmids described by Drouillard et al., an increase in final concentration of almost 45% and an increase in productivity of about 83% were observed. This shows that an efficient in vivo fucosylation is possible even without the high expression of the recombinant 2′-FL biosynthesis genes. Our study emphasizes the need for balanced activities of biosynthesis enzymes for an efficient whole cell synthesis approach. A further improvement of the 2′-FL formation via the de novo pathway might be feasible by increasing the carbon flux towards GDP-L-fucose.
In this study we constructed and improved an expression plasmid-free E. coli strain capable of the whole cell biosynthesis of the human milk oligosaccharide 2′-fucosyllactose from lactose and glycerol. The recombinant genes needed for the expression of a fucosyllactose biosynthesis pathway were integrated into the chromosome of E. coli JM109 as individual expression cassettes. By comparing strains expressing the GDP-L-fucose de novo- and the salvage-pathway, strains with one or two copies of the fucosyltransferase gene, and by measuring intracellular levels of GDP-L-fucose, we could identify bottlenecks in the 2′-FL biosynthesis for our production system. By a large-scale fed-batch cultivation we could demonstrate the efficient whole cell synthesis of 2′-fucosyllactose using a plasmid-free production strain without the use of antibiotics as selection markers.
Bacterial strains, media, and chemicals
All strains constructed are based on the lacZ-negative, but lacY-positive laboratory strain E. coli JM109 (Table 1 and Figure 2). If not stated otherwise, E. coli strains were grown at 37°C in LB medium. The minimal medium used for shake flask cultivation had the following composition: KH2PO4 3 g l-1, K2HPO4 12 g l-1, (NH4)2SO4 5 g l-1, MgSO4 · 7H2O 0.3 g l-1, CaCl2 · 2H2O 0.015 g l-1, NaCl 0.1 g l-1, glycerol 10 g l-1, FeSO4 · 7H2O/sodium citrate 15 ml l-1 (from the solution of 7.5 g l-1 FeSO4 · 7H2O and 100 g l-1 sodium citrate), thiamine 7.5 μg l-1, trace element solution 33 ml l-1. Antibiotics for strain constructions were used at the following final concentrations: ampicillin 100 μg ml-1, kanamycin 50 μg ml-1, chloramphenicol 50 μg ml-1. Difco MacConkey agar base was purchased from Nordwald (Germany). 2′-fucosyllactose standard was purchased from IsoSep (Sweden); GDP-L-fucose was from Jennewein Biotechnologie (Germany). All other chemicals and reagents were from Sigma-Aldrich or Roth (Germany) and were of the highest purity available.
Construction of plasmids
All used and constructed plasmids are listed in Table 1. The reading frames of manB, manC, gmd/wcaG, and fkp were individually cloned into the NdeI and BamHI sites of the expression vector pJF119ΔN , respectively. manB was subcloned from plasmid pCAW48 to yield pJF-manB. The gene manC was subcloned from plasmid pCAW49 to yield pJF-manC. A PCR product containing the reading frames of gmd and wcaG, as previously described , was digested with NdeI and BglII enzymes and ligated to vector pJF119ΔN DNA which had been digested with NdeI plus BamHI. This yielded plasmid pJF-gmdwcaG. The gene fkp was subcloned from plasmid pMJC54 to yield pJF-fkp. The reading frame of the fucosyltransferase gene futC was subcloned from plasmid pCAW55 into pJF119ΔN using NdeI and PstI restriction sites. The plasmid pJF-gmdwcaG was further treated with HindIII and ligated with a HindIII digested FRT-cat-FRT fragment derived from plasmid pCAS30-FRT-cat-FRT and transformed into E. coli DH5α. Plasmids pJF-manB and pJF-futC were treated with SphI and ligated with a SphI digested FRT-cat-FRT fragment derived from plasmid pCAS30-FRT-cat-FRT, respectively. Plasmid pJF-manC was hydrolyzed by SalI and ScaI and ligated with a 2.4 kb SalI/ScaI fragment received from plasmid pJF-crtY-FRT-kan-FRT containing FRT-kan-FRT cassette. Finally, a FRT-cat-FRT SalI fragment was subcloned from plasmid pQE31-FRT-cat-FRT into SalI hydrolyzed pJF-fkp.
Chromosomal integration of expression cassettes
The individual expression cassettes of manB, manC, gmd-wcaG, fkp and futC including the FRT-flanked antibiotic-resistance genes from plasmid pJF-manB-FRT-cat-FRT, pJF-manC-FRT-kan-FRT, pJF-gmdwcaG-FRT-cat-FRT, pJF-fkp-FRT-cat-FRT, and pJF-futC-FRT-cat-FRT, respectively, were amplified by PCR. The oligonucleotide primers for the amplification of the expression cassettes are listed in Additional file 1: Table S1. For the chromosomal integration of the expression cassettes, the purified PCR products were consecutively transformed into E. coli JM109 carrying plasmid pKD46. Expression of the λ-Red enzymes and the preparation of competent cells were carried out as described previously [32, 35]. Competent cells were electroporated with 0.2-0.4 μg of PCR product. After electroporation, the cells were resuspended in 1 ml LB-medium and incubated at 30°C for 12 h with shaking. Subsequently, the cell suspension was spread onto LB-agar plates containing chloramphenicol or kanamycin, according to the antibiotic resistance cassette in use. Antibiotic-resistant clones were assayed on MacConkey agar plates containing 1% of the respective sugar, corresponding to the targeted genes responsible for sugar degradation. Clones, that stayed pale on MacConkey agar after incubation over night at 37°C, were checked regarding correct recombination by control PCR. After each successful integration the antibiotic resistance cassette was eliminated using the plasmid pCP20 as previously described .
Shake flask experiments for 2′-fucosyllactose production
To determine 2′-FL productivity, strains were cultivated in 250 ml shake flasks with 25 ml minimal medium containing 10 g l-1 glycerol as carbon source for growth. IPTG was added to a final concentration of 0.5 mM when cells had reached an optical density (OD600) between 0.4 and 0.6 and lactose (2 g l-1 final concentration) was added. Furthermore, cultures of strains expressing fkp were supplemented with L-fucose (2 g l-1 final concentration) at time of induction. 4 hours and 24 hours after induction, 10 ml culture samples were spun down (3500 rpm, 15 min); supernatants were stored at -20°C until HPLC analysis. Cell pellets were washed with 5 ml of deionized water and spun down as before. Afterwards, pellets were resuspended in 1 ml of deionized water and disrupted by boiling (5 min, 100°C). After another centrifugation (25 min at 5100 rpm), supernatants were stored at -20°C until HPLC analysis.
Determination of 2′-fucosyllactose and lactose concentrations
Oligosaccharide concentrations in shake flask experiments and fed-batch fermentation were determined by HPLC of the 2-aminobenzoic acid-labeled saccharides. Samples and standards of 2′-FL and lactose were derivatized with anthranilic acid in presence of sodium cyanoborohydride . HPLC analysis was performed on Dionex HPLC Instrument (Germany), installed with a Chromeleon Software, Gina autosampler, P580 pumps, and a RF2000 fluorescence detector. Products were analyzed on a Luna C18 (2) reversed phase column (250 mm × 4.6 mm, 5 μm, Phenomenex, Germany). Mobile phase consisted of solvent 1 (aqueous solution containing tetrahydrofuran 1% (v/v), orthophosphoric acid 0.425% (v/v) and 1-butylamine 0,3% (v/v)) and solvent 2 (acetonitrile). With a flow rate of 1 ml min-1, a gradient was applied with 97.5% solvent 1/2.5% solvent 2 at beginning and 80.5% solvent 1/19.5% solvent 2 after 25 minutes followed by a 4 minute isocratic period with 80.5% solvent 1/19.5% solvent 2 and a 5 minute equilibration period with starting conditions. Standards and samples were analyzed in duplicates and standard curves were created from 6 different concentrations.
Measurement of intracellular GDP-L-fucose concentration
The E. coli strains JM109 gwBC-F1, JM109 gwBC-F1-fkp, JM109 gwBC-F2, and JM109 gwBC-F2-fkp were cultivated in shake flasks at 37°C in 100 ml minimal medium containing 1% glycerol. At an OD600 of 0.4 the gene expression was induced by addition of IPTG (0.5 mM final concentration). For cultures of E. coli JM109 gwBC-F1-fkp and E. coli JM109 gwBC-F2-fkp, L-fucose was added to a final concentration of 0.2% (w/v). 4 and 12 hours after induction, 25 ml of the culture were harvested by centrifugation (3500 rpm, 15 min), cells were washed with 5 ml deionized cold water, resuspended in 1 ml water and then disrupted by boiling (100°C, 2 min). After centrifugation (14000 rpm, 20 min), the supernatant was analyzed by HPLC. GDP-L-fucose was detected by UV-photometry at 254 nm (Dionex HPLC Instrument (as described above) installed with a diode array detector (Dionex, Germany)). As mobile phase a phosphate-buffer (solvent A: 30 mM potassium-phosphate, pH 6.0; 5 mM tetrabutylammonium hydrogen sulfate; 2% acetonitrile) and acetonitrile (solvent B) was used. As stationary phase, a reverse phase HPLC column (Gemini-NX C18, 250 × 4 mm (Phenomenex, Germany)) was used. The following flow gradient with a flow rate of 1.5 ml min-1 was applied: 0 to 10 min linear gradient from 100% solvent A/0% solvent B to 98% solvent A/2% solvent B, 10 to 30 min linear gradient from 98% solvent A/2% solvent B to 60% solvent A/40% solvent B, 30 to 30.10 min linear gradient from 60% solvent A/40% solvent B to 100% solvent A/0% solvent B, 30.10 to 35 min isocratic conditions to equilibrate the column at 100% solvent A/0% solvent B. GDP-L-fucose was identified by co-chromatography using authentic standard compound and by analysis of its UV–vis spectra. For the quantification of GDP-L-fucose the integrated peak areas were compared to HPLC standard curves of authentic standards.
Assessment of genetic stability of E. coli JM109 gwBC-F2
Assuming, that loss or mutation of chromosomally integrated genes would lead to shifts or loss in productivity, genetic stability of the strain E. coli JM109 gwBC-F2 was analyzed by cultivating the strain for more than 100 generations before analyzing the 2′-FL yield. To cultivate the strain for over 100 generations, 10ml cultures of E. coli JM109 gwBC-F2 in glycerol minimal medium were incubated for 24 hours, before measuring OD600 and using the culture to inoculate a fresh shake flask to OD600 of 0.01. Passed generations were calculated by OD600. After 100 generations, the production of 2′-FL was determined as described above.
Scale-up of 2′-FL production employing E. coli JM109 gwBC-F2 was performed in a 30 l stirred-tank reactor (Bioengineering AG, Switzerland) with a batch volume of 8.4 l and a total feed volume of 5.1 l using mineral salt medium modified from Wilms et al. and glycerol as carbon source. Medium used for preculture and batch fermentation contained (NH4)2SO4 2.68 g l-1, (NH4)2-H-citrate 1 g l-1, glycerol 26.42 g l-1, K2HPO4 14.6 g l-1, MgSO4 0.241 g l-1, Na2SO4 2 g l-1, NaH2PO4 · H2O 4 g l-1, NH4Cl 0.5 g l-1, thiamine 10 mg l-1, and trace element solution 3 ml l-1.
Glycerol-feed consisted of glycerol 629.08 g l-1, MgSO4 23.5 g l-1, thiamine 0.6 g l-1 and trace element solution 119 ml l-1. As nitrogen-source, (NH4)2HPO4 396 g l-1 was deployed and for 2′-FL production, a lactose solution 150 g l-1 was fed.
with F [l h-1] being the feeding rate, μset [h-1] the desired growth rate, m [g g-1 h-1] the specific maintenance coefficient (calculated to be 0.04 g g-1 h-1), YX/S [g g-1] the specific yield coefficient of biomass from substrate (estimated from shake flask experiments to be 0.29 g g-1, data not shown), cx0 [g l-1] the biomass concentration at beginning of the feeding phase (7.9 g l-1), V0 [l] the working volume of the reactor at beginning of the feeding phase (8.4 l), cs0 [g l-1] the glycerol concentration in the feed (629.1 g l-1), and t [h] the feeding time . Lactose feeding also began with induction and the flow rate was set to 40.5% of the feeding rate calculated for the glycerol feed for the first 10 hours after induction. It was set to 50.6% of the glycerol feeding rate calculated above for the next 6.5 hours and set to a fixed rate of 9.25 l h-1 for the final 6 hours of the process. These adjustments of the lactose feeding rate were chosen to prevent lactose limitation and extensive lactose accumulation. Lactose feeding was stopped short before glycerol feeding to minimize the amount of remaining lactose. Cell biomass was determined by measuring OD600 and cell dry weight.
Determination of glycerol and acetate concentrations
Remaining glycerol and accumulated acetate were analyzed in the supernatant at the endpoint of fermentation. Glycerol was measured using a glycerol test-kit for foodstuffs and other materials (r-biopharm, Germany), whereas the acetate concentration was measured via HPLC as follows. Culture supernatant was boiled for 5 minutes and centrifuged for 15 minutes at 14000 rpm. After centrifugation, the supernatant was used for HPLC analysis on an Agilent 1100 Series HPLC system (Agilent Technologies, USA), equipped with ChemStation for LC 3D systems software, column heater, QuatPump, degasser, a RI-71 refractive index detector (Showa Denko, Japan), and an organic-acid column (300 mm × 8 mm, CS-Chromatographie Service, Germany). The mobile phase consisted of 5 mM sulfuric acid with a flow rate of 1 ml min-1. Samples were analyzed in duplicates and the standard curve was created from 5 different concentrations.
Isolation and analysis of 2′-fucosyllactose
For further analysis, 2′-fucosyllactose was isolated from 50 ml of the fed-batch fermentation broth by activated charcoal chromatography and gel-filtration. For cell lysis, a 50 ml sample of fermentation broth was incubated at 100°C for 20 minutes. After subsequent centrifugation, supernatant was applied to a column (26 × 300 mm) filled with equal weight proportions of activated charcoal (Merck, Germany) and Celite 545 (Fluka, Germany). The column was washed with 2 column volumes of water and 2′-fucosyllactose was eluted by an ethanol gradient. Fractions containing 2′-fucosyllactose were pooled and further purified on a gel-filtration column (26 × 1000 mm) containing Bio-Gel P-2 (Bio-Rad, Germany). The purified 2′-fucosyllactose was analyzed by mass spectrometry and nuclear magnetic resonance spectroscopy. The mass was determined using a Bruker microTOF-Q system (Bruker, Germany) with electron spray ionization and the NMR spectra were recorded at 296 K using a Bruker Avance 500 spectrometer (Bruker, Germany).
The authors are grateful to Prof. Laurie Comstock (Harvard University) for providing us with plasmid pMJC54, to Katrin Wohlbolt and Dr. Birgit Claasen (Institute of Organic Chemistry, Universität Stuttgart) for MS and NMR measurements. This work was supported by contract research ‘Glycomics/Glycobiology’ of the Baden-Württemberg Stiftung.
- Zivkovic AM, German JB, Lebrilla CB, Mills DA: Human milk glycobiome and its impact on the infant gastrointestinal microbiota. Proc Natl Acad Sci U S A. 2011, 108 (Suppl. 1): 4653-4658.View ArticleGoogle Scholar
- Ninonuevo MR, Park Y, Yin H, Zhang J, Ward RE, Clowers BH, German JB, Freeman SL, Killeen K, Grimm R, Lebrilla CB: A strategy for annotating the human milk glycome. J Agric Food Chem. 2006, 54: 7471-7480. 10.1021/jf0615810.View ArticleGoogle Scholar
- Kunz C, Rudloff S, Baier W, Klein N, Strobel S: Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr. 2000, 20: 699-722. 10.1146/annurev.nutr.20.1.699.View ArticleGoogle Scholar
- Totten SM, Zivkovic AM, Wu S, Ngyuen U, Freeman SL, Ruhaak LR, Darboe MK, German JB, Prentice AM, Lebrilla CB: Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. J Proteome Res. 2012, 11: 6124-6133.Google Scholar
- Blank D, Dotz V, Geyer R, Kunz C: Human milk oligosaccharides and Lewis blood group: individual high-throughput sample profiling to enhance conclusions from functional studies. Adv Nutr. 2012, 3: 440S-449S. 10.3945/an.111.001446.View ArticleGoogle Scholar
- Chaturvedi P, Warren CD, Altaye M, Morrow AL, Ruiz-Palacios G, Pickering LK, Newburg DS: Fucosylated human milk oligosaccharides vary between individuals and over the course of lactation. Glycobiology. 2001, 11: 365-372. 10.1093/glycob/11.5.365.View ArticleGoogle Scholar
- Kunz C, Rudloff S: Health promoting aspects of milk oligosaccharides. Int Dairy J. 2006, 16: 1341-1346. 10.1016/j.idairyj.2006.06.020.View ArticleGoogle Scholar
- Newburg DS, Ruiz-Palacios GM, Altaye M, Chaturvedi P, Meinzen-Derr J, Guerrero MDL, Morrow AL: Innate protection conferred by fucosylated oligosaccharides of human milk against diarrhea in breastfed infants. Glycobiology. 2004, 14: 253-263.View ArticleGoogle Scholar
- Bode L: Recent advances on structure, metabolism, and function of human milk oligosaccharides. J Nutr. 2006, 136: 2127-2130.Google Scholar
- Yu ZT, Chen C, Kling DE, Liu B, McCoy JM, Merighi M, Heidtman MND: The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology. 2012, 23: 169-177.View ArticleGoogle Scholar
- Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Guerrero MDL, Meinzer-Derr JK, Farkas T, Chaturvedi P, Pickering LK, Newburg DS: Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr. 2004, 145: 297-303. 10.1016/j.jpeds.2004.04.054.View ArticleGoogle Scholar
- Anderson A, Donald AS: Improved method for the isolation of 2 ′ fucosyllactose from human milk. J Chromatogr. 1981, 211: 170-174. 10.1016/S0021-9673(00)81188-7View ArticleGoogle Scholar
- Fernandez-Mayoralas A, Martin-Lomas M: Synthesis of 3- and 2′-fucosyl-lactose and 3, 2′-difucosyl-lactose from partially benzylated lactose derivatives. Carbohydr Res. 1986, 154: 93-101. 10.1016/S0008-6215(00)90025-9.View ArticleGoogle Scholar
- Albermann C, Piepersberg W, Wehmeier UF: Synthesis of the milk oligosaccharide 2′-fucosyllactose using recombinant bacterial enzymes. Carbohydr Res. 2001, 334: 97-103. 10.1016/S0008-6215(01)00177-X.View ArticleGoogle Scholar
- Wang G, Boulton PG, Chan NWC, Palcic MM, Taylor DE: Novel Helicobacter pylori alpha1, 2-fucosyltransferase, a key enzyme in the synthesis of Lewis antigens. Microbiology. 1999, 145: 3245-3253.View ArticleGoogle Scholar
- Li M, Liu X-W, Shao J, Shen J, Jia Q, Yi W, Song JK, Woodward R, Chow CS, Wang PG: Characterization of a novel alpha1, 2-fucosyltransferase of Escherichia coli O128:B12 and functional investigation of its common motif. Biochemistry. 2008, 47: 378-387. 10.1021/bi701345v.View ArticleGoogle Scholar
- Coyne MJ, Reinap B, Lee MM, Comstock LE: Human symbionts use a host-like pathway for surface fucosylation. Science. 2005, 307: 1778-1781. 10.1126/science.1106469.View ArticleGoogle Scholar
- Yi W, Liu X, Li Y, Li J, Xia C, Zhou G, Zhang W, Zhao W, Chen X, Wang PG: Remodeling bacterial polysaccharides by metabolic pathway engineering. Proc Natl Acad Sci U S A. 2009, 106: 4207-4212. 10.1073/pnas.0812432106.View ArticleGoogle Scholar
- Andrianopoulos K, Wang L, Reeves PR: Identification of the fucose synthetase gene in the colanic acid gene cluster of Escherichia coli K-12. J Bacteriol. 1998, 180: 998-1001.Google Scholar
- Albermann C, Distler J, Piepersberg W: Preparative synthesis of GDP-beta-L-fucose by recombinant enzymes from enterobacterial sources. Glycobiology. 2000, 10: 875-881. 10.1093/glycob/10.9.875.View ArticleGoogle Scholar
- Mattila P, Räbinä J, Hortling S, Helin J, Renkonen R: Functional expression of Escherichia coli enzymes synthesizing GDP-L-fucose from inherent GDP-D-mannose in Saccharomyces cerevisiae. Glycobiology. 2000, 10: 1041-1047. 10.1093/glycob/10.10.1041.View ArticleGoogle Scholar
- Byun SG, Kim MD, Lee WH, Lee KJ, Han NS, Seo JH: Production of GDP-L-fucose, L-fucose donor for fucosyloligosaccharide synthesis, in recombinant Escherichia coli. Appl Microbiol Biotechnol. 2007, 74: 768-775. 10.1007/s00253-006-0730-x.View ArticleGoogle Scholar
- Koizumi S, Endo T, Tabata K, Nagano H, Ohnishi J, Ozaki A: Large-scale production of GDP-fucose and Lewis X by bacterial coupling. J Ind Microbiol Biotechnol. 2000, 25: 213-217. 10.1038/sj.jim.7000055.View ArticleGoogle Scholar
- Dumon C, Bosso C, Utille JP, Heyraud A, Samain E: Production of Lewis x tetrasaccharides by metabolically engineered Escherichia coli. Chembiochem. 2006, 7: 359-365. 10.1002/cbic.200500293.View ArticleGoogle Scholar
- Lee WH, Pathanibul P, Quarterman J, Jo JH, Han NS, Miller MJ, Jin YS, Seo JH: Whole cell biosynthesis of a functional oligosaccharide, 2′-fucosyllactose, using engineered Escherichia coli. Microb Cell Fact. 2012, 11: 48- 10.1186/1475-2859-11-48.View ArticleGoogle Scholar
- Dumon C, Priem B, Martin SL, Heyraud A, Bosso C, Samain E: In vivo fucosylation of lacto-N-neotetraose and lacto-N-neohexaose by heterologous expression of Helicobacter pylori alpha-1, 3 fucosyltransferase in engineered Escherichia coli. Glycoconj J. 2001, 18: 465-474. 10.1023/A:1016086118274.View ArticleGoogle Scholar
- Friehs K: Plasmid copy number and plasmid stability. Adv Biochem Eng Biotechnol. 2004, 86: 47-82.Google Scholar
- Jones KL, Kim SW, Keasling JD: Low-copy plasmids can perform as well as or better than high-copy plasmids for metabolic engineering of bacteria. Metab Eng. 2000, 2: 328-338. 10.1006/mben.2000.0161.View ArticleGoogle Scholar
- Martinez-Morales F, Borges AC, Martinez A, Shanmugam KT, Ingram LO: Chromosomal integration of heterologous DNA in Escherichia coli with precise removal of markers and replicons used during construction. J Bacteriol. 1999, 181: 7143-7148.Google Scholar
- Chiang CJ, Chen PT, Chao YP: Replicon-free and markerless methods for genomic insertion of DNAs in phage attachment sites and controlled expression of chromosomal genes in Escherichia coli. Biotechnol Bioeng. 2008, 101: 985-995. 10.1002/bit.21976.View ArticleGoogle Scholar
- Tyo KEJ, Ajikumar PK, Stephanopoulos G: Stabilized gene duplication enables long-term selection-free heterologous pathway expression. Nat Biotechnol. 2009, 27: 760-765. 10.1038/nbt.1555.View ArticleGoogle Scholar
- Albermann C, Trachtmann N, Sprenger GA: A simple and reliable method to conduct and monitor expression cassette integration into the Escherichia coli chromosome. Biotechnol J. 2010, 5: 32-38. 10.1002/biot.200900193.View ArticleGoogle Scholar
- Sabido A, Martínez LM, De Anda R, Martínez A, Bolívar F, Gosset G: A novel plasmid vector designed for chromosomal gene integration and expression: Use for developing a genetically stable Escherichia coli melanin production strain. Plasmid. 2013, 69: 16-23. 10.1016/j.plasmid.2012.04.005.View ArticleGoogle Scholar
- Cherepanov PP, Wackernagel W: Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene. 1995, 158: 9-14. 10.1016/0378-1119(95)00193-A.View ArticleGoogle Scholar
- Datsenko KA, Wanner BL: One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 2000, 97: 6640-6645. 10.1073/pnas.120163297.View ArticleGoogle Scholar
- Vallon T, Ghanegaonkar S, Vielhauer O, Müller A, Albermann C, Sprenger GA, Reuss M, Lemuth K: Quantitative analysis of isoprenoid diphosphate intermediates in recombinant and wild-type Escherichia coli strains. Appl Microbiol Biotechnol. 2008, 81: 175-182. 10.1007/s00253-008-1707-8.View ArticleGoogle Scholar
- Lemuth K, Steuer K, Albermann C: Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin. Microb Cell Fact. 2011, 10: 29- 10.1186/1475-2859-10-29.View ArticleGoogle Scholar
- Albermann C, Ghanegaonkar S, Lemuth K, Vallon T, Reuss M, Armbruster W, Sprenger GA: Biosynthesis of the vitamin E compound delta-tocotrienol in recombinant Escherichia coli cells. Chembiochem. 2008, 9: 2524-2533. 10.1002/cbic.200800242.View ArticleGoogle Scholar
- Schwab C, Gänzle M: Lactic acid bacteria fermentation of human milk oligosaccharide components, human milk oligosaccharides and galactooligosaccharides. FEMS Microbiol Lett. 2011, 315: 141-148. 10.1111/j.1574-6968.2010.02185.x.View ArticleGoogle Scholar
- Newburg DS, Ruiz-Palacios GM, Morrow AL: Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr. 2005, 25: 37-58. 10.1146/annurev.nutr.25.050304.092553.View ArticleGoogle Scholar
- Bode L: Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012, 22: 1147-1162. 10.1093/glycob/cws074.View ArticleGoogle Scholar
- Ruiz-Palacios GM, Cervantes LE, Ramos P, Chavez-Munguia B, Newburg DS: Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem. 2003, 278: 14112-14120. 10.1074/jbc.M207744200.View ArticleGoogle Scholar
- Yu Z-T, Chen C, Kling DE, Liu B, McCoy JM, Merighi M, Heidtman M, Newburg DS: The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology. 2013, 23: 169-177. 10.1093/glycob/cws138.View ArticleGoogle Scholar
- Bajza I, Boutet J, Dékany G, Hederos M, Horvath F, Kovács-Penzes P, Kröger L, Olsson J, Pérez IF, Röhrig C, Schroven A, Vrasidas I: Synthesis of 2′-O-Fucosyllactose. WIPO Patent Application WO/2010/115935Google Scholar
- Drouillard S, Driguez H, Samain E: Large-scale synthesis of H-antigen oligosaccharides by expressing Helicobacter pylori alpha1, 2-fucosyltransferase in metabolically engineered Escherichia coli cells. Angew Chem Int Ed Engl. 2006, 45: 1778-1780. 10.1002/anie.200503427.View ArticleGoogle Scholar
- Lee WH, Chin YW, Han NS, Kim MD, Seo JH: Enhanced production of GDP-L-fucose by overexpression of NADPH regenerator in recombinant Escherichia coli. Appl Microbiol Biotechnol. 2011, 91: 967-976. 10.1007/s00253-011-3271-x.View ArticleGoogle Scholar
- Stein DB, Lin YN, Lin CH: Characterization of Helicobacter pylori α1, 2-fucosyltransferase for enzymatic synthesis of tumor-associated antigens. Adv Synth Catal. 2008, 350: 2313-2321. 10.1002/adsc.200800435.View ArticleGoogle Scholar
- Rozkov A, Avignone-Rossa CA, Ertl PF, Jones P, O’Kennedy RD, Smith JJ, Dale JW, Bushell ME: Characterization of the metabolic burden on Escherichia coli DH1 cells imposed by the presence of a plasmid containing a gene therapy sequence. Biotechnol Bioeng. 2004, 88: 909-915. 10.1002/bit.20327.View ArticleGoogle Scholar
- Sturla L, Bisso A, Zanardi D, Benatti U, De Flora A, Tonetti M: Expression, purification and characterization of GDP-D-mannose 4, 6-dehydratase from Escherichia coli. FEBS Lett. 1997, 412: 126-130. 10.1016/S0014-5793(97)00762-X.View ArticleGoogle Scholar
- Somoza JR, Menon S, Schmidt H, Joseph-McCarthy D, Dessen A, Stahl ML, Somers WS, Sullivan FX: Structural and kinetic analysis of Escherichia coli GDP-mannose 4, 6 dehydratase provides insights into the enzyme’s catalytic mechanism and regulation by GDP-fucose. Structure. 2000, 8: 123-135. 10.1016/S0969-2126(00)00088-5.View ArticleGoogle Scholar
- Lee WH, Han NS, Park YC, Seo JH: Modulation of guanosine 5′-diphosphate-D-mannose metabolism in recombinant Escherichia coli for production of guanosine 5′-diphosphate-L-fucose. Bioresour Technol. 2009, 100: 6143-6148. 10.1016/j.biortech.2009.07.035.View ArticleGoogle Scholar
- Pan JG, Rhee JS, Lebeault JM: Physiological constraints in increasing biomass concentration of Escherichia coli B in fed-batch culture. Biotechnol Lett. 1987, 9: 89-94. 10.1007/BF01032744.View ArticleGoogle Scholar
- Anumula KR: Quantitative determination of monosaccharides in glycoproteins by high-performance liquid chromatography with highly sensitive fluorescence detection. Anal Biochem. 1994, 220: 275-283. 10.1006/abio.1994.1338.View ArticleGoogle Scholar
- Wilms B, Hauck A, Reuss M, Syldatk C, Mattes R, Siemann M, Altenbuchner J: High-cell-density fermentation for production of L-N-carbamoylase using an expression system based on the Escherichia coli rhaBAD promoter. Biotechnol Bioeng. 2001, 73: 95-103. 10.1002/bit.1041.View ArticleGoogle Scholar
- Wenzel M, Müller A, Siemann-Herzberg M, Altenbuchner J: Self-inducible Bacillus subtilis expression system for reliable and inexpensive protein production by high-cell-density fermentation. Appl Environ Microbiol. 2011, 77: 6419-6425. 10.1128/AEM.05219-11.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.